Loading the section…
The price of Kura Oncology, Inc. (KURA) on October 9, 2026 is 10.60 USD, +0.76% on the day. Over 52 weeks the stock traded between 7.36 USD and 13.90 USD; the price now sits 50% of the way up that range. Over the past year the price changed by +5.16%. Market capitalization is 940.89 million USD, rank 115 among 372 stocks of the same industry with a known capitalization.
Closing prices for 9 October 2026
Next earnings report: 3 November 2026 · Earnings calendar
Change over the period shown (line colour): +6.75 %
Kura Oncology, Inc. trades on Nasdaq under the ticker KURA. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks KURA has traded between 7.36 $ and 13.90 $. As of 9 October 2026 the price stood 49.56 % of the way from the 52-week low to the high.
Over one year KURA shares rose 5.16 %; over six months they rose 22.26 %. Volatility over 90 days is 52.46 %. Dividends are not included: this is price change only, as of 9 October 2026.
The company reported a loss over the last four quarters, so a price-to-earnings ratio is not calculated. Price to sales is 13.1, above the sector median of 4.0. Price to book is 8.7, above the sector median of 2.5. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 9 October 2026 | 10.52 | 10.68 | 10.38 | 10.60 | 1M |
| 8 October 2026 | 10.52 | 10.55 | 10.16 | 10.52 | 2M |
| 7 October 2026 | 10.43 | 10.99 | 10.32 | 10.67 | 1M |
| 6 October 2026 | 10.75 | 10.89 |
The series is stated in the current share scale after splits; dividends are not included in the price
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Kura Oncology, Inc. (KURA) is a public company in the healthcare sector. Its common stock trade on NASDAQ.
Over the trailing twelve months as reported to 2026-03-31, revenue was 71.6m $, net income was -294.6m $. Incorporated in US.
This summary is compiled automatically from SEC filings and exchange data.
Address:4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO, CA, 92121, US
Kura Oncology, Inc. reported revenue of 72M $ and a net loss of 295M $ over the last four quarters. Net margin is −411.19 %. Earnings per share are −3.35 $. Market capitalisation is 941M $.
KURA has a return on equity of −273.05 %, below the sector median of −41.68 %. Return on assets is −45.14 %, below the sector median of −32.11 %. Operating margin is −443.54 %, below the sector median of −26.84 %.
| 1.2B |
| PFEPfizer, Inc. | 28.28 | +1.65 % | 922M |
| ABTAbbott Laboratories | 99.60 | +1.13 % | 921M |
| BMYBristol-Myers Squibb Company | 59.12 | −0.77 % | 714M |
| REGNRegeneron Pharmaceuticals, Inc. | 746.54 | +0.94 % | 555M |
| 10.34 |
| 10.53 |
| 1M |
| 5 October 2026 | 10.73 | 10.80 | 10.29 | 10.62 | 1M |
| 2 October 2026 | 10.85 | 10.97 | 10.59 | 10.65 | 2M |
| 1 October 2026 | 11.10 | 11.13 | 10.59 | 10.65 | 2M |
| 30 September 2026 | 10.90 | 10.95 | 10.61 | 10.71 | 2M |
| 29 September 2026 | 10.65 | 10.91 | 10.54 | 10.81 | 2M |
| 28 September 2026 | 10.71 | 10.83 | 10.36 | 10.61 | 2M |
| 25 September 2026 | 10.88 | 10.96 | 10.75 | 10.76 | 1M |
| 24 September 2026 | 11.00 | 11.08 | 10.66 | 10.86 | 2M |
| 23 September 2026 | 11.73 | 11.81 | 10.83 | 11.04 | 3M |
| 22 September 2026 | 11.80 | 11.99 | 11.59 | 11.73 | 2M |
| 21 September 2026 | 11.86 | 12.00 | 11.49 | 11.60 | 2M |
| 18 September 2026 | 11.64 | 11.84 | 11.56 | 11.73 | 3M |
| 17 September 2026 | 11.39 | 12.20 | 11.35 | 11.72 | 2M |
| 16 September 2026 | 11.31 | 11.52 | 11.14 | 11.20 | 2M |
| 15 September 2026 | 11.48 | 11.48 | 11.03 | 11.30 | 2M |
| 14 September 2026 | 11.37 | 11.68 | 11.25 | 11.56 | 1M |